Links to Exploration step
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Safety and Clinical Activity of a Combination Therapy Comprising Two Antibody-Based Targeting Agents for the Treatment of Non-Hodgkin Lymphoma: Results of a Phase I/II Study Evaluating the Immunoconjugate Inotuzumab Ozogamicin With Rituximab</title><author><name sortKey="Fayad, Luis" sort="Fayad, Luis" uniqKey="Fayad L" first="Luis" last="Fayad">Luis Fayad</name><affiliation><nlm:aff id="aff1">Luis Fayad, MD Anderson Cancer Center, Houston, TX; Fritz Offner, Ghent University Hospital, Ghent; Gregor Verhoef, University Hospitals, Leuven, Belgium; Mitchell R. Smith, Fox Chase Cancer Center, Philadelphia; Joseph Boni, Pfizer, Collegeville, PA; Peter Johnson, University of Southampton, Southhampton; Ama Rohatiner, St. Bartholomew's Hospital, London, United Kingdom; Jonathan L. Kaufman, Emory University, Atlanta, GA; Anjali Advani, Taussig Cancer Institute, The Cleveland Clinic, Cleveland, OH; James Foran, University of Alabama at Birmingham, Birmingham, AL; Georg Hess, Johannes Gutenberg University, Mainz, Germany; Bertrand Coiffier, Hospices Civils de Lyon and University Lyon, Lyon, France; Myron Czuczman, Roswell Park Cancer Institute, Buffalo, NY; Eva Giné, Hospital Clínic, Barcelona, Spain; Simon Durrant, Royal Brisbane Hospital, Brisbane, Australia; Michelle Kneissl and Erik Vandendries, Pfizer, Cambridge, MA; Kenneth T. Luu and Steven Y. Hua, Pfizer, La Jolla, CA; and Nam H. Dang, University of Florida, Gainesville, FL.</nlm:aff></affiliation></author><author><name sortKey="Offner, Fritz" sort="Offner, Fritz" uniqKey="Offner F" first="Fritz" last="Offner">Fritz Offner</name><affiliation><nlm:aff id="aff1">Luis Fayad, MD Anderson Cancer Center, Houston, TX; Fritz Offner, Ghent University Hospital, Ghent; Gregor Verhoef, University Hospitals, Leuven, Belgium; Mitchell R. Smith, Fox Chase Cancer Center, Philadelphia; Joseph Boni, Pfizer, Collegeville, PA; Peter Johnson, University of Southampton, Southhampton; Ama Rohatiner, St. Bartholomew's Hospital, London, United Kingdom; Jonathan L. Kaufman, Emory University, Atlanta, GA; Anjali Advani, Taussig Cancer Institute, The Cleveland Clinic, Cleveland, OH; James Foran, University of Alabama at Birmingham, Birmingham, AL; Georg Hess, Johannes Gutenberg University, Mainz, Germany; Bertrand Coiffier, Hospices Civils de Lyon and University Lyon, Lyon, France; Myron Czuczman, Roswell Park Cancer Institute, Buffalo, NY; Eva Giné, Hospital Clínic, Barcelona, Spain; Simon Durrant, Royal Brisbane Hospital, Brisbane, Australia; Michelle Kneissl and Erik Vandendries, Pfizer, Cambridge, MA; Kenneth T. Luu and Steven Y. Hua, Pfizer, La Jolla, CA; and Nam H. Dang, University of Florida, Gainesville, FL.</nlm:aff></affiliation></author><author><name sortKey="Smith, Mitchell R" sort="Smith, Mitchell R" uniqKey="Smith M" first="Mitchell R." last="Smith">Mitchell R. Smith</name><affiliation><nlm:aff id="aff1">Luis Fayad, MD Anderson Cancer Center, Houston, TX; Fritz Offner, Ghent University Hospital, Ghent; Gregor Verhoef, University Hospitals, Leuven, Belgium; Mitchell R. Smith, Fox Chase Cancer Center, Philadelphia; Joseph Boni, Pfizer, Collegeville, PA; Peter Johnson, University of Southampton, Southhampton; Ama Rohatiner, St. Bartholomew's Hospital, London, United Kingdom; Jonathan L. Kaufman, Emory University, Atlanta, GA; Anjali Advani, Taussig Cancer Institute, The Cleveland Clinic, Cleveland, OH; James Foran, University of Alabama at Birmingham, Birmingham, AL; Georg Hess, Johannes Gutenberg University, Mainz, Germany; Bertrand Coiffier, Hospices Civils de Lyon and University Lyon, Lyon, France; Myron Czuczman, Roswell Park Cancer Institute, Buffalo, NY; Eva Giné, Hospital Clínic, Barcelona, Spain; Simon Durrant, Royal Brisbane Hospital, Brisbane, Australia; Michelle Kneissl and Erik Vandendries, Pfizer, Cambridge, MA; Kenneth T. Luu and Steven Y. Hua, Pfizer, La Jolla, CA; and Nam H. Dang, University of Florida, Gainesville, FL.</nlm:aff></affiliation></author><author><name sortKey="Verhoef, Gregor" sort="Verhoef, Gregor" uniqKey="Verhoef G" first="Gregor" last="Verhoef">Gregor Verhoef</name><affiliation><nlm:aff id="aff1">Luis Fayad, MD Anderson Cancer Center, Houston, TX; Fritz Offner, Ghent University Hospital, Ghent; Gregor Verhoef, University Hospitals, Leuven, Belgium; Mitchell R. Smith, Fox Chase Cancer Center, Philadelphia; Joseph Boni, Pfizer, Collegeville, PA; Peter Johnson, University of Southampton, Southhampton; Ama Rohatiner, St. Bartholomew's Hospital, London, United Kingdom; Jonathan L. Kaufman, Emory University, Atlanta, GA; Anjali Advani, Taussig Cancer Institute, The Cleveland Clinic, Cleveland, OH; James Foran, University of Alabama at Birmingham, Birmingham, AL; Georg Hess, Johannes Gutenberg University, Mainz, Germany; Bertrand Coiffier, Hospices Civils de Lyon and University Lyon, Lyon, France; Myron Czuczman, Roswell Park Cancer Institute, Buffalo, NY; Eva Giné, Hospital Clínic, Barcelona, Spain; Simon Durrant, Royal Brisbane Hospital, Brisbane, Australia; Michelle Kneissl and Erik Vandendries, Pfizer, Cambridge, MA; Kenneth T. Luu and Steven Y. Hua, Pfizer, La Jolla, CA; and Nam H. Dang, University of Florida, Gainesville, FL.</nlm:aff></affiliation></author><author><name sortKey="Johnson, Peter" sort="Johnson, Peter" uniqKey="Johnson P" first="Peter" last="Johnson">Peter Johnson</name><affiliation><nlm:aff id="aff1">Luis Fayad, MD Anderson Cancer Center, Houston, TX; Fritz Offner, Ghent University Hospital, Ghent; Gregor Verhoef, University Hospitals, Leuven, Belgium; Mitchell R. Smith, Fox Chase Cancer Center, Philadelphia; Joseph Boni, Pfizer, Collegeville, PA; Peter Johnson, University of Southampton, Southhampton; Ama Rohatiner, St. Bartholomew's Hospital, London, United Kingdom; Jonathan L. Kaufman, Emory University, Atlanta, GA; Anjali Advani, Taussig Cancer Institute, The Cleveland Clinic, Cleveland, OH; James Foran, University of Alabama at Birmingham, Birmingham, AL; Georg Hess, Johannes Gutenberg University, Mainz, Germany; Bertrand Coiffier, Hospices Civils de Lyon and University Lyon, Lyon, France; Myron Czuczman, Roswell Park Cancer Institute, Buffalo, NY; Eva Giné, Hospital Clínic, Barcelona, Spain; Simon Durrant, Royal Brisbane Hospital, Brisbane, Australia; Michelle Kneissl and Erik Vandendries, Pfizer, Cambridge, MA; Kenneth T. Luu and Steven Y. Hua, Pfizer, La Jolla, CA; and Nam H. Dang, University of Florida, Gainesville, FL.</nlm:aff></affiliation></author><author><name sortKey="Kaufman, Jonathan L" sort="Kaufman, Jonathan L" uniqKey="Kaufman J" first="Jonathan L." last="Kaufman">Jonathan L. Kaufman</name><affiliation><nlm:aff id="aff1">Luis Fayad, MD Anderson Cancer Center, Houston, TX; Fritz Offner, Ghent University Hospital, Ghent; Gregor Verhoef, University Hospitals, Leuven, Belgium; Mitchell R. Smith, Fox Chase Cancer Center, Philadelphia; Joseph Boni, Pfizer, Collegeville, PA; Peter Johnson, University of Southampton, Southhampton; Ama Rohatiner, St. Bartholomew's Hospital, London, United Kingdom; Jonathan L. Kaufman, Emory University, Atlanta, GA; Anjali Advani, Taussig Cancer Institute, The Cleveland Clinic, Cleveland, OH; James Foran, University of Alabama at Birmingham, Birmingham, AL; Georg Hess, Johannes Gutenberg University, Mainz, Germany; Bertrand Coiffier, Hospices Civils de Lyon and University Lyon, Lyon, France; Myron Czuczman, Roswell Park Cancer Institute, Buffalo, NY; Eva Giné, Hospital Clínic, Barcelona, Spain; Simon Durrant, Royal Brisbane Hospital, Brisbane, Australia; Michelle Kneissl and Erik Vandendries, Pfizer, Cambridge, MA; Kenneth T. Luu and Steven Y. Hua, Pfizer, La Jolla, CA; and Nam H. Dang, University of Florida, Gainesville, FL.</nlm:aff></affiliation></author><author><name sortKey="Rohatiner, Ama" sort="Rohatiner, Ama" uniqKey="Rohatiner A" first="Ama" last="Rohatiner">Ama Rohatiner</name><affiliation><nlm:aff id="aff1">Luis Fayad, MD Anderson Cancer Center, Houston, TX; Fritz Offner, Ghent University Hospital, Ghent; Gregor Verhoef, University Hospitals, Leuven, Belgium; Mitchell R. Smith, Fox Chase Cancer Center, Philadelphia; Joseph Boni, Pfizer, Collegeville, PA; Peter Johnson, University of Southampton, Southhampton; Ama Rohatiner, St. Bartholomew's Hospital, London, United Kingdom; Jonathan L. Kaufman, Emory University, Atlanta, GA; Anjali Advani, Taussig Cancer Institute, The Cleveland Clinic, Cleveland, OH; James Foran, University of Alabama at Birmingham, Birmingham, AL; Georg Hess, Johannes Gutenberg University, Mainz, Germany; Bertrand Coiffier, Hospices Civils de Lyon and University Lyon, Lyon, France; Myron Czuczman, Roswell Park Cancer Institute, Buffalo, NY; Eva Giné, Hospital Clínic, Barcelona, Spain; Simon Durrant, Royal Brisbane Hospital, Brisbane, Australia; Michelle Kneissl and Erik Vandendries, Pfizer, Cambridge, MA; Kenneth T. Luu and Steven Y. Hua, Pfizer, La Jolla, CA; and Nam H. Dang, University of Florida, Gainesville, FL.</nlm:aff></affiliation></author><author><name sortKey="Advani, Anjali" sort="Advani, Anjali" uniqKey="Advani A" first="Anjali" last="Advani">Anjali Advani</name><affiliation><nlm:aff id="aff1">Luis Fayad, MD Anderson Cancer Center, Houston, TX; Fritz Offner, Ghent University Hospital, Ghent; Gregor Verhoef, University Hospitals, Leuven, Belgium; Mitchell R. Smith, Fox Chase Cancer Center, Philadelphia; Joseph Boni, Pfizer, Collegeville, PA; Peter Johnson, University of Southampton, Southhampton; Ama Rohatiner, St. Bartholomew's Hospital, London, United Kingdom; Jonathan L. Kaufman, Emory University, Atlanta, GA; Anjali Advani, Taussig Cancer Institute, The Cleveland Clinic, Cleveland, OH; James Foran, University of Alabama at Birmingham, Birmingham, AL; Georg Hess, Johannes Gutenberg University, Mainz, Germany; Bertrand Coiffier, Hospices Civils de Lyon and University Lyon, Lyon, France; Myron Czuczman, Roswell Park Cancer Institute, Buffalo, NY; Eva Giné, Hospital Clínic, Barcelona, Spain; Simon Durrant, Royal Brisbane Hospital, Brisbane, Australia; Michelle Kneissl and Erik Vandendries, Pfizer, Cambridge, MA; Kenneth T. Luu and Steven Y. Hua, Pfizer, La Jolla, CA; and Nam H. Dang, University of Florida, Gainesville, FL.</nlm:aff></affiliation></author><author><name sortKey="Foran, James" sort="Foran, James" uniqKey="Foran J" first="James" last="Foran">James Foran</name><affiliation><nlm:aff id="aff1">Luis Fayad, MD Anderson Cancer Center, Houston, TX; Fritz Offner, Ghent University Hospital, Ghent; Gregor Verhoef, University Hospitals, Leuven, Belgium; Mitchell R. Smith, Fox Chase Cancer Center, Philadelphia; Joseph Boni, Pfizer, Collegeville, PA; Peter Johnson, University of Southampton, Southhampton; Ama Rohatiner, St. Bartholomew's Hospital, London, United Kingdom; Jonathan L. Kaufman, Emory University, Atlanta, GA; Anjali Advani, Taussig Cancer Institute, The Cleveland Clinic, Cleveland, OH; James Foran, University of Alabama at Birmingham, Birmingham, AL; Georg Hess, Johannes Gutenberg University, Mainz, Germany; Bertrand Coiffier, Hospices Civils de Lyon and University Lyon, Lyon, France; Myron Czuczman, Roswell Park Cancer Institute, Buffalo, NY; Eva Giné, Hospital Clínic, Barcelona, Spain; Simon Durrant, Royal Brisbane Hospital, Brisbane, Australia; Michelle Kneissl and Erik Vandendries, Pfizer, Cambridge, MA; Kenneth T. Luu and Steven Y. Hua, Pfizer, La Jolla, CA; and Nam H. Dang, University of Florida, Gainesville, FL.</nlm:aff></affiliation></author><author><name sortKey="Hess, Georg" sort="Hess, Georg" uniqKey="Hess G" first="Georg" last="Hess">Georg Hess</name><affiliation><nlm:aff id="aff1">Luis Fayad, MD Anderson Cancer Center, Houston, TX; Fritz Offner, Ghent University Hospital, Ghent; Gregor Verhoef, University Hospitals, Leuven, Belgium; Mitchell R. Smith, Fox Chase Cancer Center, Philadelphia; Joseph Boni, Pfizer, Collegeville, PA; Peter Johnson, University of Southampton, Southhampton; Ama Rohatiner, St. Bartholomew's Hospital, London, United Kingdom; Jonathan L. Kaufman, Emory University, Atlanta, GA; Anjali Advani, Taussig Cancer Institute, The Cleveland Clinic, Cleveland, OH; James Foran, University of Alabama at Birmingham, Birmingham, AL; Georg Hess, Johannes Gutenberg University, Mainz, Germany; Bertrand Coiffier, Hospices Civils de Lyon and University Lyon, Lyon, France; Myron Czuczman, Roswell Park Cancer Institute, Buffalo, NY; Eva Giné, Hospital Clínic, Barcelona, Spain; Simon Durrant, Royal Brisbane Hospital, Brisbane, Australia; Michelle Kneissl and Erik Vandendries, Pfizer, Cambridge, MA; Kenneth T. Luu and Steven Y. Hua, Pfizer, La Jolla, CA; and Nam H. Dang, University of Florida, Gainesville, FL.</nlm:aff></affiliation></author><author><name sortKey="Coiffier, Bertrand" sort="Coiffier, Bertrand" uniqKey="Coiffier B" first="Bertrand" last="Coiffier">Bertrand Coiffier</name><affiliation><nlm:aff id="aff1">Luis Fayad, MD Anderson Cancer Center, Houston, TX; Fritz Offner, Ghent University Hospital, Ghent; Gregor Verhoef, University Hospitals, Leuven, Belgium; Mitchell R. Smith, Fox Chase Cancer Center, Philadelphia; Joseph Boni, Pfizer, Collegeville, PA; Peter Johnson, University of Southampton, Southhampton; Ama Rohatiner, St. Bartholomew's Hospital, London, United Kingdom; Jonathan L. Kaufman, Emory University, Atlanta, GA; Anjali Advani, Taussig Cancer Institute, The Cleveland Clinic, Cleveland, OH; James Foran, University of Alabama at Birmingham, Birmingham, AL; Georg Hess, Johannes Gutenberg University, Mainz, Germany; Bertrand Coiffier, Hospices Civils de Lyon and University Lyon, Lyon, France; Myron Czuczman, Roswell Park Cancer Institute, Buffalo, NY; Eva Giné, Hospital Clínic, Barcelona, Spain; Simon Durrant, Royal Brisbane Hospital, Brisbane, Australia; Michelle Kneissl and Erik Vandendries, Pfizer, Cambridge, MA; Kenneth T. Luu and Steven Y. Hua, Pfizer, La Jolla, CA; and Nam H. Dang, University of Florida, Gainesville, FL.</nlm:aff></affiliation></author><author><name sortKey="Czuczman, Myron" sort="Czuczman, Myron" uniqKey="Czuczman M" first="Myron" last="Czuczman">Myron Czuczman</name><affiliation><nlm:aff id="aff1">Luis Fayad, MD Anderson Cancer Center, Houston, TX; Fritz Offner, Ghent University Hospital, Ghent; Gregor Verhoef, University Hospitals, Leuven, Belgium; Mitchell R. Smith, Fox Chase Cancer Center, Philadelphia; Joseph Boni, Pfizer, Collegeville, PA; Peter Johnson, University of Southampton, Southhampton; Ama Rohatiner, St. Bartholomew's Hospital, London, United Kingdom; Jonathan L. Kaufman, Emory University, Atlanta, GA; Anjali Advani, Taussig Cancer Institute, The Cleveland Clinic, Cleveland, OH; James Foran, University of Alabama at Birmingham, Birmingham, AL; Georg Hess, Johannes Gutenberg University, Mainz, Germany; Bertrand Coiffier, Hospices Civils de Lyon and University Lyon, Lyon, France; Myron Czuczman, Roswell Park Cancer Institute, Buffalo, NY; Eva Giné, Hospital Clínic, Barcelona, Spain; Simon Durrant, Royal Brisbane Hospital, Brisbane, Australia; Michelle Kneissl and Erik Vandendries, Pfizer, Cambridge, MA; Kenneth T. Luu and Steven Y. Hua, Pfizer, La Jolla, CA; and Nam H. Dang, University of Florida, Gainesville, FL.</nlm:aff></affiliation></author><author><name sortKey="Gine, Eva" sort="Gine, Eva" uniqKey="Gine E" first="Eva" last="Giné">Eva Giné</name><affiliation><nlm:aff id="aff1">Luis Fayad, MD Anderson Cancer Center, Houston, TX; Fritz Offner, Ghent University Hospital, Ghent; Gregor Verhoef, University Hospitals, Leuven, Belgium; Mitchell R. Smith, Fox Chase Cancer Center, Philadelphia; Joseph Boni, Pfizer, Collegeville, PA; Peter Johnson, University of Southampton, Southhampton; Ama Rohatiner, St. Bartholomew's Hospital, London, United Kingdom; Jonathan L. Kaufman, Emory University, Atlanta, GA; Anjali Advani, Taussig Cancer Institute, The Cleveland Clinic, Cleveland, OH; James Foran, University of Alabama at Birmingham, Birmingham, AL; Georg Hess, Johannes Gutenberg University, Mainz, Germany; Bertrand Coiffier, Hospices Civils de Lyon and University Lyon, Lyon, France; Myron Czuczman, Roswell Park Cancer Institute, Buffalo, NY; Eva Giné, Hospital Clínic, Barcelona, Spain; Simon Durrant, Royal Brisbane Hospital, Brisbane, Australia; Michelle Kneissl and Erik Vandendries, Pfizer, Cambridge, MA; Kenneth T. Luu and Steven Y. Hua, Pfizer, La Jolla, CA; and Nam H. Dang, University of Florida, Gainesville, FL.</nlm:aff></affiliation></author><author><name sortKey="Durrant, Simon" sort="Durrant, Simon" uniqKey="Durrant S" first="Simon" last="Durrant">Simon Durrant</name><affiliation><nlm:aff id="aff1">Luis Fayad, MD Anderson Cancer Center, Houston, TX; Fritz Offner, Ghent University Hospital, Ghent; Gregor Verhoef, University Hospitals, Leuven, Belgium; Mitchell R. Smith, Fox Chase Cancer Center, Philadelphia; Joseph Boni, Pfizer, Collegeville, PA; Peter Johnson, University of Southampton, Southhampton; Ama Rohatiner, St. Bartholomew's Hospital, London, United Kingdom; Jonathan L. Kaufman, Emory University, Atlanta, GA; Anjali Advani, Taussig Cancer Institute, The Cleveland Clinic, Cleveland, OH; James Foran, University of Alabama at Birmingham, Birmingham, AL; Georg Hess, Johannes Gutenberg University, Mainz, Germany; Bertrand Coiffier, Hospices Civils de Lyon and University Lyon, Lyon, France; Myron Czuczman, Roswell Park Cancer Institute, Buffalo, NY; Eva Giné, Hospital Clínic, Barcelona, Spain; Simon Durrant, Royal Brisbane Hospital, Brisbane, Australia; Michelle Kneissl and Erik Vandendries, Pfizer, Cambridge, MA; Kenneth T. Luu and Steven Y. Hua, Pfizer, La Jolla, CA; and Nam H. Dang, University of Florida, Gainesville, FL.</nlm:aff></affiliation></author><author><name sortKey="Kneissl, Michelle" sort="Kneissl, Michelle" uniqKey="Kneissl M" first="Michelle" last="Kneissl">Michelle Kneissl</name><affiliation><nlm:aff id="aff1">Luis Fayad, MD Anderson Cancer Center, Houston, TX; Fritz Offner, Ghent University Hospital, Ghent; Gregor Verhoef, University Hospitals, Leuven, Belgium; Mitchell R. Smith, Fox Chase Cancer Center, Philadelphia; Joseph Boni, Pfizer, Collegeville, PA; Peter Johnson, University of Southampton, Southhampton; Ama Rohatiner, St. Bartholomew's Hospital, London, United Kingdom; Jonathan L. Kaufman, Emory University, Atlanta, GA; Anjali Advani, Taussig Cancer Institute, The Cleveland Clinic, Cleveland, OH; James Foran, University of Alabama at Birmingham, Birmingham, AL; Georg Hess, Johannes Gutenberg University, Mainz, Germany; Bertrand Coiffier, Hospices Civils de Lyon and University Lyon, Lyon, France; Myron Czuczman, Roswell Park Cancer Institute, Buffalo, NY; Eva Giné, Hospital Clínic, Barcelona, Spain; Simon Durrant, Royal Brisbane Hospital, Brisbane, Australia; Michelle Kneissl and Erik Vandendries, Pfizer, Cambridge, MA; Kenneth T. Luu and Steven Y. Hua, Pfizer, La Jolla, CA; and Nam H. Dang, University of Florida, Gainesville, FL.</nlm:aff></affiliation></author><author><name sortKey="Luu, Kenneth T" sort="Luu, Kenneth T" uniqKey="Luu K" first="Kenneth T." last="Luu">Kenneth T. Luu</name><affiliation><nlm:aff id="aff1">Luis Fayad, MD Anderson Cancer Center, Houston, TX; Fritz Offner, Ghent University Hospital, Ghent; Gregor Verhoef, University Hospitals, Leuven, Belgium; Mitchell R. Smith, Fox Chase Cancer Center, Philadelphia; Joseph Boni, Pfizer, Collegeville, PA; Peter Johnson, University of Southampton, Southhampton; Ama Rohatiner, St. Bartholomew's Hospital, London, United Kingdom; Jonathan L. Kaufman, Emory University, Atlanta, GA; Anjali Advani, Taussig Cancer Institute, The Cleveland Clinic, Cleveland, OH; James Foran, University of Alabama at Birmingham, Birmingham, AL; Georg Hess, Johannes Gutenberg University, Mainz, Germany; Bertrand Coiffier, Hospices Civils de Lyon and University Lyon, Lyon, France; Myron Czuczman, Roswell Park Cancer Institute, Buffalo, NY; Eva Giné, Hospital Clínic, Barcelona, Spain; Simon Durrant, Royal Brisbane Hospital, Brisbane, Australia; Michelle Kneissl and Erik Vandendries, Pfizer, Cambridge, MA; Kenneth T. Luu and Steven Y. Hua, Pfizer, La Jolla, CA; and Nam H. Dang, University of Florida, Gainesville, FL.</nlm:aff></affiliation></author><author><name sortKey="Hua, Steven Y" sort="Hua, Steven Y" uniqKey="Hua S" first="Steven Y." last="Hua">Steven Y. Hua</name><affiliation><nlm:aff id="aff1">Luis Fayad, MD Anderson Cancer Center, Houston, TX; Fritz Offner, Ghent University Hospital, Ghent; Gregor Verhoef, University Hospitals, Leuven, Belgium; Mitchell R. Smith, Fox Chase Cancer Center, Philadelphia; Joseph Boni, Pfizer, Collegeville, PA; Peter Johnson, University of Southampton, Southhampton; Ama Rohatiner, St. Bartholomew's Hospital, London, United Kingdom; Jonathan L. Kaufman, Emory University, Atlanta, GA; Anjali Advani, Taussig Cancer Institute, The Cleveland Clinic, Cleveland, OH; James Foran, University of Alabama at Birmingham, Birmingham, AL; Georg Hess, Johannes Gutenberg University, Mainz, Germany; Bertrand Coiffier, Hospices Civils de Lyon and University Lyon, Lyon, France; Myron Czuczman, Roswell Park Cancer Institute, Buffalo, NY; Eva Giné, Hospital Clínic, Barcelona, Spain; Simon Durrant, Royal Brisbane Hospital, Brisbane, Australia; Michelle Kneissl and Erik Vandendries, Pfizer, Cambridge, MA; Kenneth T. Luu and Steven Y. Hua, Pfizer, La Jolla, CA; and Nam H. Dang, University of Florida, Gainesville, FL.</nlm:aff></affiliation></author><author><name sortKey="Boni, Joseph" sort="Boni, Joseph" uniqKey="Boni J" first="Joseph" last="Boni">Joseph Boni</name><affiliation><nlm:aff id="aff1">Luis Fayad, MD Anderson Cancer Center, Houston, TX; Fritz Offner, Ghent University Hospital, Ghent; Gregor Verhoef, University Hospitals, Leuven, Belgium; Mitchell R. Smith, Fox Chase Cancer Center, Philadelphia; Joseph Boni, Pfizer, Collegeville, PA; Peter Johnson, University of Southampton, Southhampton; Ama Rohatiner, St. Bartholomew's Hospital, London, United Kingdom; Jonathan L. Kaufman, Emory University, Atlanta, GA; Anjali Advani, Taussig Cancer Institute, The Cleveland Clinic, Cleveland, OH; James Foran, University of Alabama at Birmingham, Birmingham, AL; Georg Hess, Johannes Gutenberg University, Mainz, Germany; Bertrand Coiffier, Hospices Civils de Lyon and University Lyon, Lyon, France; Myron Czuczman, Roswell Park Cancer Institute, Buffalo, NY; Eva Giné, Hospital Clínic, Barcelona, Spain; Simon Durrant, Royal Brisbane Hospital, Brisbane, Australia; Michelle Kneissl and Erik Vandendries, Pfizer, Cambridge, MA; Kenneth T. Luu and Steven Y. Hua, Pfizer, La Jolla, CA; and Nam H. Dang, University of Florida, Gainesville, FL.</nlm:aff></affiliation></author><author><name sortKey="Vandendries, Erik" sort="Vandendries, Erik" uniqKey="Vandendries E" first="Erik" last="Vandendries">Erik Vandendries</name><affiliation><nlm:aff id="aff1">Luis Fayad, MD Anderson Cancer Center, Houston, TX; Fritz Offner, Ghent University Hospital, Ghent; Gregor Verhoef, University Hospitals, Leuven, Belgium; Mitchell R. Smith, Fox Chase Cancer Center, Philadelphia; Joseph Boni, Pfizer, Collegeville, PA; Peter Johnson, University of Southampton, Southhampton; Ama Rohatiner, St. Bartholomew's Hospital, London, United Kingdom; Jonathan L. Kaufman, Emory University, Atlanta, GA; Anjali Advani, Taussig Cancer Institute, The Cleveland Clinic, Cleveland, OH; James Foran, University of Alabama at Birmingham, Birmingham, AL; Georg Hess, Johannes Gutenberg University, Mainz, Germany; Bertrand Coiffier, Hospices Civils de Lyon and University Lyon, Lyon, France; Myron Czuczman, Roswell Park Cancer Institute, Buffalo, NY; Eva Giné, Hospital Clínic, Barcelona, Spain; Simon Durrant, Royal Brisbane Hospital, Brisbane, Australia; Michelle Kneissl and Erik Vandendries, Pfizer, Cambridge, MA; Kenneth T. Luu and Steven Y. Hua, Pfizer, La Jolla, CA; and Nam H. Dang, University of Florida, Gainesville, FL.</nlm:aff></affiliation></author><author><name sortKey="Dang, Nam H" sort="Dang, Nam H" uniqKey="Dang N" first="Nam H." last="Dang">Nam H. Dang</name><affiliation><nlm:aff id="aff1">Luis Fayad, MD Anderson Cancer Center, Houston, TX; Fritz Offner, Ghent University Hospital, Ghent; Gregor Verhoef, University Hospitals, Leuven, Belgium; Mitchell R. Smith, Fox Chase Cancer Center, Philadelphia; Joseph Boni, Pfizer, Collegeville, PA; Peter Johnson, University of Southampton, Southhampton; Ama Rohatiner, St. Bartholomew's Hospital, London, United Kingdom; Jonathan L. Kaufman, Emory University, Atlanta, GA; Anjali Advani, Taussig Cancer Institute, The Cleveland Clinic, Cleveland, OH; James Foran, University of Alabama at Birmingham, Birmingham, AL; Georg Hess, Johannes Gutenberg University, Mainz, Germany; Bertrand Coiffier, Hospices Civils de Lyon and University Lyon, Lyon, France; Myron Czuczman, Roswell Park Cancer Institute, Buffalo, NY; Eva Giné, Hospital Clínic, Barcelona, Spain; Simon Durrant, Royal Brisbane Hospital, Brisbane, Australia; Michelle Kneissl and Erik Vandendries, Pfizer, Cambridge, MA; Kenneth T. Luu and Steven Y. Hua, Pfizer, La Jolla, CA; and Nam H. Dang, University of Florida, Gainesville, FL.</nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">23295790</idno><idno type="pmc">4878046</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4878046</idno><idno type="RBID">PMC:4878046</idno><idno type="doi">10.1200/JCO.2012.42.7211</idno><date when="2013">2013</date><idno type="wicri:Area/Pmc/Corpus">000452</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000452</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Safety and Clinical Activity of a Combination Therapy Comprising Two Antibody-Based Targeting Agents for the Treatment of Non-Hodgkin Lymphoma: Results of a Phase I/II Study Evaluating the Immunoconjugate Inotuzumab Ozogamicin With Rituximab</title><author><name sortKey="Fayad, Luis" sort="Fayad, Luis" uniqKey="Fayad L" first="Luis" last="Fayad">Luis Fayad</name><affiliation><nlm:aff id="aff1">Luis Fayad, MD Anderson Cancer Center, Houston, TX; Fritz Offner, Ghent University Hospital, Ghent; Gregor Verhoef, University Hospitals, Leuven, Belgium; Mitchell R. Smith, Fox Chase Cancer Center, Philadelphia; Joseph Boni, Pfizer, Collegeville, PA; Peter Johnson, University of Southampton, Southhampton; Ama Rohatiner, St. Bartholomew's Hospital, London, United Kingdom; Jonathan L. Kaufman, Emory University, Atlanta, GA; Anjali Advani, Taussig Cancer Institute, The Cleveland Clinic, Cleveland, OH; James Foran, University of Alabama at Birmingham, Birmingham, AL; Georg Hess, Johannes Gutenberg University, Mainz, Germany; Bertrand Coiffier, Hospices Civils de Lyon and University Lyon, Lyon, France; Myron Czuczman, Roswell Park Cancer Institute, Buffalo, NY; Eva Giné, Hospital Clínic, Barcelona, Spain; Simon Durrant, Royal Brisbane Hospital, Brisbane, Australia; Michelle Kneissl and Erik Vandendries, Pfizer, Cambridge, MA; Kenneth T. Luu and Steven Y. Hua, Pfizer, La Jolla, CA; and Nam H. Dang, University of Florida, Gainesville, FL.</nlm:aff></affiliation></author><author><name sortKey="Offner, Fritz" sort="Offner, Fritz" uniqKey="Offner F" first="Fritz" last="Offner">Fritz Offner</name><affiliation><nlm:aff id="aff1">Luis Fayad, MD Anderson Cancer Center, Houston, TX; Fritz Offner, Ghent University Hospital, Ghent; Gregor Verhoef, University Hospitals, Leuven, Belgium; Mitchell R. Smith, Fox Chase Cancer Center, Philadelphia; Joseph Boni, Pfizer, Collegeville, PA; Peter Johnson, University of Southampton, Southhampton; Ama Rohatiner, St. Bartholomew's Hospital, London, United Kingdom; Jonathan L. Kaufman, Emory University, Atlanta, GA; Anjali Advani, Taussig Cancer Institute, The Cleveland Clinic, Cleveland, OH; James Foran, University of Alabama at Birmingham, Birmingham, AL; Georg Hess, Johannes Gutenberg University, Mainz, Germany; Bertrand Coiffier, Hospices Civils de Lyon and University Lyon, Lyon, France; Myron Czuczman, Roswell Park Cancer Institute, Buffalo, NY; Eva Giné, Hospital Clínic, Barcelona, Spain; Simon Durrant, Royal Brisbane Hospital, Brisbane, Australia; Michelle Kneissl and Erik Vandendries, Pfizer, Cambridge, MA; Kenneth T. Luu and Steven Y. Hua, Pfizer, La Jolla, CA; and Nam H. Dang, University of Florida, Gainesville, FL.</nlm:aff></affiliation></author><author><name sortKey="Smith, Mitchell R" sort="Smith, Mitchell R" uniqKey="Smith M" first="Mitchell R." last="Smith">Mitchell R. Smith</name><affiliation><nlm:aff id="aff1">Luis Fayad, MD Anderson Cancer Center, Houston, TX; Fritz Offner, Ghent University Hospital, Ghent; Gregor Verhoef, University Hospitals, Leuven, Belgium; Mitchell R. Smith, Fox Chase Cancer Center, Philadelphia; Joseph Boni, Pfizer, Collegeville, PA; Peter Johnson, University of Southampton, Southhampton; Ama Rohatiner, St. Bartholomew's Hospital, London, United Kingdom; Jonathan L. Kaufman, Emory University, Atlanta, GA; Anjali Advani, Taussig Cancer Institute, The Cleveland Clinic, Cleveland, OH; James Foran, University of Alabama at Birmingham, Birmingham, AL; Georg Hess, Johannes Gutenberg University, Mainz, Germany; Bertrand Coiffier, Hospices Civils de Lyon and University Lyon, Lyon, France; Myron Czuczman, Roswell Park Cancer Institute, Buffalo, NY; Eva Giné, Hospital Clínic, Barcelona, Spain; Simon Durrant, Royal Brisbane Hospital, Brisbane, Australia; Michelle Kneissl and Erik Vandendries, Pfizer, Cambridge, MA; Kenneth T. Luu and Steven Y. Hua, Pfizer, La Jolla, CA; and Nam H. Dang, University of Florida, Gainesville, FL.</nlm:aff></affiliation></author><author><name sortKey="Verhoef, Gregor" sort="Verhoef, Gregor" uniqKey="Verhoef G" first="Gregor" last="Verhoef">Gregor Verhoef</name><affiliation><nlm:aff id="aff1">Luis Fayad, MD Anderson Cancer Center, Houston, TX; Fritz Offner, Ghent University Hospital, Ghent; Gregor Verhoef, University Hospitals, Leuven, Belgium; Mitchell R. Smith, Fox Chase Cancer Center, Philadelphia; Joseph Boni, Pfizer, Collegeville, PA; Peter Johnson, University of Southampton, Southhampton; Ama Rohatiner, St. Bartholomew's Hospital, London, United Kingdom; Jonathan L. Kaufman, Emory University, Atlanta, GA; Anjali Advani, Taussig Cancer Institute, The Cleveland Clinic, Cleveland, OH; James Foran, University of Alabama at Birmingham, Birmingham, AL; Georg Hess, Johannes Gutenberg University, Mainz, Germany; Bertrand Coiffier, Hospices Civils de Lyon and University Lyon, Lyon, France; Myron Czuczman, Roswell Park Cancer Institute, Buffalo, NY; Eva Giné, Hospital Clínic, Barcelona, Spain; Simon Durrant, Royal Brisbane Hospital, Brisbane, Australia; Michelle Kneissl and Erik Vandendries, Pfizer, Cambridge, MA; Kenneth T. Luu and Steven Y. Hua, Pfizer, La Jolla, CA; and Nam H. Dang, University of Florida, Gainesville, FL.</nlm:aff></affiliation></author><author><name sortKey="Johnson, Peter" sort="Johnson, Peter" uniqKey="Johnson P" first="Peter" last="Johnson">Peter Johnson</name><affiliation><nlm:aff id="aff1">Luis Fayad, MD Anderson Cancer Center, Houston, TX; Fritz Offner, Ghent University Hospital, Ghent; Gregor Verhoef, University Hospitals, Leuven, Belgium; Mitchell R. Smith, Fox Chase Cancer Center, Philadelphia; Joseph Boni, Pfizer, Collegeville, PA; Peter Johnson, University of Southampton, Southhampton; Ama Rohatiner, St. Bartholomew's Hospital, London, United Kingdom; Jonathan L. Kaufman, Emory University, Atlanta, GA; Anjali Advani, Taussig Cancer Institute, The Cleveland Clinic, Cleveland, OH; James Foran, University of Alabama at Birmingham, Birmingham, AL; Georg Hess, Johannes Gutenberg University, Mainz, Germany; Bertrand Coiffier, Hospices Civils de Lyon and University Lyon, Lyon, France; Myron Czuczman, Roswell Park Cancer Institute, Buffalo, NY; Eva Giné, Hospital Clínic, Barcelona, Spain; Simon Durrant, Royal Brisbane Hospital, Brisbane, Australia; Michelle Kneissl and Erik Vandendries, Pfizer, Cambridge, MA; Kenneth T. Luu and Steven Y. Hua, Pfizer, La Jolla, CA; and Nam H. Dang, University of Florida, Gainesville, FL.</nlm:aff></affiliation></author><author><name sortKey="Kaufman, Jonathan L" sort="Kaufman, Jonathan L" uniqKey="Kaufman J" first="Jonathan L." last="Kaufman">Jonathan L. Kaufman</name><affiliation><nlm:aff id="aff1">Luis Fayad, MD Anderson Cancer Center, Houston, TX; Fritz Offner, Ghent University Hospital, Ghent; Gregor Verhoef, University Hospitals, Leuven, Belgium; Mitchell R. Smith, Fox Chase Cancer Center, Philadelphia; Joseph Boni, Pfizer, Collegeville, PA; Peter Johnson, University of Southampton, Southhampton; Ama Rohatiner, St. Bartholomew's Hospital, London, United Kingdom; Jonathan L. Kaufman, Emory University, Atlanta, GA; Anjali Advani, Taussig Cancer Institute, The Cleveland Clinic, Cleveland, OH; James Foran, University of Alabama at Birmingham, Birmingham, AL; Georg Hess, Johannes Gutenberg University, Mainz, Germany; Bertrand Coiffier, Hospices Civils de Lyon and University Lyon, Lyon, France; Myron Czuczman, Roswell Park Cancer Institute, Buffalo, NY; Eva Giné, Hospital Clínic, Barcelona, Spain; Simon Durrant, Royal Brisbane Hospital, Brisbane, Australia; Michelle Kneissl and Erik Vandendries, Pfizer, Cambridge, MA; Kenneth T. Luu and Steven Y. Hua, Pfizer, La Jolla, CA; and Nam H. Dang, University of Florida, Gainesville, FL.</nlm:aff></affiliation></author><author><name sortKey="Rohatiner, Ama" sort="Rohatiner, Ama" uniqKey="Rohatiner A" first="Ama" last="Rohatiner">Ama Rohatiner</name><affiliation><nlm:aff id="aff1">Luis Fayad, MD Anderson Cancer Center, Houston, TX; Fritz Offner, Ghent University Hospital, Ghent; Gregor Verhoef, University Hospitals, Leuven, Belgium; Mitchell R. Smith, Fox Chase Cancer Center, Philadelphia; Joseph Boni, Pfizer, Collegeville, PA; Peter Johnson, University of Southampton, Southhampton; Ama Rohatiner, St. Bartholomew's Hospital, London, United Kingdom; Jonathan L. Kaufman, Emory University, Atlanta, GA; Anjali Advani, Taussig Cancer Institute, The Cleveland Clinic, Cleveland, OH; James Foran, University of Alabama at Birmingham, Birmingham, AL; Georg Hess, Johannes Gutenberg University, Mainz, Germany; Bertrand Coiffier, Hospices Civils de Lyon and University Lyon, Lyon, France; Myron Czuczman, Roswell Park Cancer Institute, Buffalo, NY; Eva Giné, Hospital Clínic, Barcelona, Spain; Simon Durrant, Royal Brisbane Hospital, Brisbane, Australia; Michelle Kneissl and Erik Vandendries, Pfizer, Cambridge, MA; Kenneth T. Luu and Steven Y. Hua, Pfizer, La Jolla, CA; and Nam H. Dang, University of Florida, Gainesville, FL.</nlm:aff></affiliation></author><author><name sortKey="Advani, Anjali" sort="Advani, Anjali" uniqKey="Advani A" first="Anjali" last="Advani">Anjali Advani</name><affiliation><nlm:aff id="aff1">Luis Fayad, MD Anderson Cancer Center, Houston, TX; Fritz Offner, Ghent University Hospital, Ghent; Gregor Verhoef, University Hospitals, Leuven, Belgium; Mitchell R. Smith, Fox Chase Cancer Center, Philadelphia; Joseph Boni, Pfizer, Collegeville, PA; Peter Johnson, University of Southampton, Southhampton; Ama Rohatiner, St. Bartholomew's Hospital, London, United Kingdom; Jonathan L. Kaufman, Emory University, Atlanta, GA; Anjali Advani, Taussig Cancer Institute, The Cleveland Clinic, Cleveland, OH; James Foran, University of Alabama at Birmingham, Birmingham, AL; Georg Hess, Johannes Gutenberg University, Mainz, Germany; Bertrand Coiffier, Hospices Civils de Lyon and University Lyon, Lyon, France; Myron Czuczman, Roswell Park Cancer Institute, Buffalo, NY; Eva Giné, Hospital Clínic, Barcelona, Spain; Simon Durrant, Royal Brisbane Hospital, Brisbane, Australia; Michelle Kneissl and Erik Vandendries, Pfizer, Cambridge, MA; Kenneth T. Luu and Steven Y. Hua, Pfizer, La Jolla, CA; and Nam H. Dang, University of Florida, Gainesville, FL.</nlm:aff></affiliation></author><author><name sortKey="Foran, James" sort="Foran, James" uniqKey="Foran J" first="James" last="Foran">James Foran</name><affiliation><nlm:aff id="aff1">Luis Fayad, MD Anderson Cancer Center, Houston, TX; Fritz Offner, Ghent University Hospital, Ghent; Gregor Verhoef, University Hospitals, Leuven, Belgium; Mitchell R. Smith, Fox Chase Cancer Center, Philadelphia; Joseph Boni, Pfizer, Collegeville, PA; Peter Johnson, University of Southampton, Southhampton; Ama Rohatiner, St. Bartholomew's Hospital, London, United Kingdom; Jonathan L. Kaufman, Emory University, Atlanta, GA; Anjali Advani, Taussig Cancer Institute, The Cleveland Clinic, Cleveland, OH; James Foran, University of Alabama at Birmingham, Birmingham, AL; Georg Hess, Johannes Gutenberg University, Mainz, Germany; Bertrand Coiffier, Hospices Civils de Lyon and University Lyon, Lyon, France; Myron Czuczman, Roswell Park Cancer Institute, Buffalo, NY; Eva Giné, Hospital Clínic, Barcelona, Spain; Simon Durrant, Royal Brisbane Hospital, Brisbane, Australia; Michelle Kneissl and Erik Vandendries, Pfizer, Cambridge, MA; Kenneth T. Luu and Steven Y. Hua, Pfizer, La Jolla, CA; and Nam H. Dang, University of Florida, Gainesville, FL.</nlm:aff></affiliation></author><author><name sortKey="Hess, Georg" sort="Hess, Georg" uniqKey="Hess G" first="Georg" last="Hess">Georg Hess</name><affiliation><nlm:aff id="aff1">Luis Fayad, MD Anderson Cancer Center, Houston, TX; Fritz Offner, Ghent University Hospital, Ghent; Gregor Verhoef, University Hospitals, Leuven, Belgium; Mitchell R. Smith, Fox Chase Cancer Center, Philadelphia; Joseph Boni, Pfizer, Collegeville, PA; Peter Johnson, University of Southampton, Southhampton; Ama Rohatiner, St. Bartholomew's Hospital, London, United Kingdom; Jonathan L. Kaufman, Emory University, Atlanta, GA; Anjali Advani, Taussig Cancer Institute, The Cleveland Clinic, Cleveland, OH; James Foran, University of Alabama at Birmingham, Birmingham, AL; Georg Hess, Johannes Gutenberg University, Mainz, Germany; Bertrand Coiffier, Hospices Civils de Lyon and University Lyon, Lyon, France; Myron Czuczman, Roswell Park Cancer Institute, Buffalo, NY; Eva Giné, Hospital Clínic, Barcelona, Spain; Simon Durrant, Royal Brisbane Hospital, Brisbane, Australia; Michelle Kneissl and Erik Vandendries, Pfizer, Cambridge, MA; Kenneth T. Luu and Steven Y. Hua, Pfizer, La Jolla, CA; and Nam H. Dang, University of Florida, Gainesville, FL.</nlm:aff></affiliation></author><author><name sortKey="Coiffier, Bertrand" sort="Coiffier, Bertrand" uniqKey="Coiffier B" first="Bertrand" last="Coiffier">Bertrand Coiffier</name><affiliation><nlm:aff id="aff1">Luis Fayad, MD Anderson Cancer Center, Houston, TX; Fritz Offner, Ghent University Hospital, Ghent; Gregor Verhoef, University Hospitals, Leuven, Belgium; Mitchell R. Smith, Fox Chase Cancer Center, Philadelphia; Joseph Boni, Pfizer, Collegeville, PA; Peter Johnson, University of Southampton, Southhampton; Ama Rohatiner, St. Bartholomew's Hospital, London, United Kingdom; Jonathan L. Kaufman, Emory University, Atlanta, GA; Anjali Advani, Taussig Cancer Institute, The Cleveland Clinic, Cleveland, OH; James Foran, University of Alabama at Birmingham, Birmingham, AL; Georg Hess, Johannes Gutenberg University, Mainz, Germany; Bertrand Coiffier, Hospices Civils de Lyon and University Lyon, Lyon, France; Myron Czuczman, Roswell Park Cancer Institute, Buffalo, NY; Eva Giné, Hospital Clínic, Barcelona, Spain; Simon Durrant, Royal Brisbane Hospital, Brisbane, Australia; Michelle Kneissl and Erik Vandendries, Pfizer, Cambridge, MA; Kenneth T. Luu and Steven Y. Hua, Pfizer, La Jolla, CA; and Nam H. Dang, University of Florida, Gainesville, FL.</nlm:aff></affiliation></author><author><name sortKey="Czuczman, Myron" sort="Czuczman, Myron" uniqKey="Czuczman M" first="Myron" last="Czuczman">Myron Czuczman</name><affiliation><nlm:aff id="aff1">Luis Fayad, MD Anderson Cancer Center, Houston, TX; Fritz Offner, Ghent University Hospital, Ghent; Gregor Verhoef, University Hospitals, Leuven, Belgium; Mitchell R. Smith, Fox Chase Cancer Center, Philadelphia; Joseph Boni, Pfizer, Collegeville, PA; Peter Johnson, University of Southampton, Southhampton; Ama Rohatiner, St. Bartholomew's Hospital, London, United Kingdom; Jonathan L. Kaufman, Emory University, Atlanta, GA; Anjali Advani, Taussig Cancer Institute, The Cleveland Clinic, Cleveland, OH; James Foran, University of Alabama at Birmingham, Birmingham, AL; Georg Hess, Johannes Gutenberg University, Mainz, Germany; Bertrand Coiffier, Hospices Civils de Lyon and University Lyon, Lyon, France; Myron Czuczman, Roswell Park Cancer Institute, Buffalo, NY; Eva Giné, Hospital Clínic, Barcelona, Spain; Simon Durrant, Royal Brisbane Hospital, Brisbane, Australia; Michelle Kneissl and Erik Vandendries, Pfizer, Cambridge, MA; Kenneth T. Luu and Steven Y. Hua, Pfizer, La Jolla, CA; and Nam H. Dang, University of Florida, Gainesville, FL.</nlm:aff></affiliation></author><author><name sortKey="Gine, Eva" sort="Gine, Eva" uniqKey="Gine E" first="Eva" last="Giné">Eva Giné</name><affiliation><nlm:aff id="aff1">Luis Fayad, MD Anderson Cancer Center, Houston, TX; Fritz Offner, Ghent University Hospital, Ghent; Gregor Verhoef, University Hospitals, Leuven, Belgium; Mitchell R. Smith, Fox Chase Cancer Center, Philadelphia; Joseph Boni, Pfizer, Collegeville, PA; Peter Johnson, University of Southampton, Southhampton; Ama Rohatiner, St. Bartholomew's Hospital, London, United Kingdom; Jonathan L. Kaufman, Emory University, Atlanta, GA; Anjali Advani, Taussig Cancer Institute, The Cleveland Clinic, Cleveland, OH; James Foran, University of Alabama at Birmingham, Birmingham, AL; Georg Hess, Johannes Gutenberg University, Mainz, Germany; Bertrand Coiffier, Hospices Civils de Lyon and University Lyon, Lyon, France; Myron Czuczman, Roswell Park Cancer Institute, Buffalo, NY; Eva Giné, Hospital Clínic, Barcelona, Spain; Simon Durrant, Royal Brisbane Hospital, Brisbane, Australia; Michelle Kneissl and Erik Vandendries, Pfizer, Cambridge, MA; Kenneth T. Luu and Steven Y. Hua, Pfizer, La Jolla, CA; and Nam H. Dang, University of Florida, Gainesville, FL.</nlm:aff></affiliation></author><author><name sortKey="Durrant, Simon" sort="Durrant, Simon" uniqKey="Durrant S" first="Simon" last="Durrant">Simon Durrant</name><affiliation><nlm:aff id="aff1">Luis Fayad, MD Anderson Cancer Center, Houston, TX; Fritz Offner, Ghent University Hospital, Ghent; Gregor Verhoef, University Hospitals, Leuven, Belgium; Mitchell R. Smith, Fox Chase Cancer Center, Philadelphia; Joseph Boni, Pfizer, Collegeville, PA; Peter Johnson, University of Southampton, Southhampton; Ama Rohatiner, St. Bartholomew's Hospital, London, United Kingdom; Jonathan L. Kaufman, Emory University, Atlanta, GA; Anjali Advani, Taussig Cancer Institute, The Cleveland Clinic, Cleveland, OH; James Foran, University of Alabama at Birmingham, Birmingham, AL; Georg Hess, Johannes Gutenberg University, Mainz, Germany; Bertrand Coiffier, Hospices Civils de Lyon and University Lyon, Lyon, France; Myron Czuczman, Roswell Park Cancer Institute, Buffalo, NY; Eva Giné, Hospital Clínic, Barcelona, Spain; Simon Durrant, Royal Brisbane Hospital, Brisbane, Australia; Michelle Kneissl and Erik Vandendries, Pfizer, Cambridge, MA; Kenneth T. Luu and Steven Y. Hua, Pfizer, La Jolla, CA; and Nam H. Dang, University of Florida, Gainesville, FL.</nlm:aff></affiliation></author><author><name sortKey="Kneissl, Michelle" sort="Kneissl, Michelle" uniqKey="Kneissl M" first="Michelle" last="Kneissl">Michelle Kneissl</name><affiliation><nlm:aff id="aff1">Luis Fayad, MD Anderson Cancer Center, Houston, TX; Fritz Offner, Ghent University Hospital, Ghent; Gregor Verhoef, University Hospitals, Leuven, Belgium; Mitchell R. Smith, Fox Chase Cancer Center, Philadelphia; Joseph Boni, Pfizer, Collegeville, PA; Peter Johnson, University of Southampton, Southhampton; Ama Rohatiner, St. Bartholomew's Hospital, London, United Kingdom; Jonathan L. Kaufman, Emory University, Atlanta, GA; Anjali Advani, Taussig Cancer Institute, The Cleveland Clinic, Cleveland, OH; James Foran, University of Alabama at Birmingham, Birmingham, AL; Georg Hess, Johannes Gutenberg University, Mainz, Germany; Bertrand Coiffier, Hospices Civils de Lyon and University Lyon, Lyon, France; Myron Czuczman, Roswell Park Cancer Institute, Buffalo, NY; Eva Giné, Hospital Clínic, Barcelona, Spain; Simon Durrant, Royal Brisbane Hospital, Brisbane, Australia; Michelle Kneissl and Erik Vandendries, Pfizer, Cambridge, MA; Kenneth T. Luu and Steven Y. Hua, Pfizer, La Jolla, CA; and Nam H. Dang, University of Florida, Gainesville, FL.</nlm:aff></affiliation></author><author><name sortKey="Luu, Kenneth T" sort="Luu, Kenneth T" uniqKey="Luu K" first="Kenneth T." last="Luu">Kenneth T. Luu</name><affiliation><nlm:aff id="aff1">Luis Fayad, MD Anderson Cancer Center, Houston, TX; Fritz Offner, Ghent University Hospital, Ghent; Gregor Verhoef, University Hospitals, Leuven, Belgium; Mitchell R. Smith, Fox Chase Cancer Center, Philadelphia; Joseph Boni, Pfizer, Collegeville, PA; Peter Johnson, University of Southampton, Southhampton; Ama Rohatiner, St. Bartholomew's Hospital, London, United Kingdom; Jonathan L. Kaufman, Emory University, Atlanta, GA; Anjali Advani, Taussig Cancer Institute, The Cleveland Clinic, Cleveland, OH; James Foran, University of Alabama at Birmingham, Birmingham, AL; Georg Hess, Johannes Gutenberg University, Mainz, Germany; Bertrand Coiffier, Hospices Civils de Lyon and University Lyon, Lyon, France; Myron Czuczman, Roswell Park Cancer Institute, Buffalo, NY; Eva Giné, Hospital Clínic, Barcelona, Spain; Simon Durrant, Royal Brisbane Hospital, Brisbane, Australia; Michelle Kneissl and Erik Vandendries, Pfizer, Cambridge, MA; Kenneth T. Luu and Steven Y. Hua, Pfizer, La Jolla, CA; and Nam H. Dang, University of Florida, Gainesville, FL.</nlm:aff></affiliation></author><author><name sortKey="Hua, Steven Y" sort="Hua, Steven Y" uniqKey="Hua S" first="Steven Y." last="Hua">Steven Y. Hua</name><affiliation><nlm:aff id="aff1">Luis Fayad, MD Anderson Cancer Center, Houston, TX; Fritz Offner, Ghent University Hospital, Ghent; Gregor Verhoef, University Hospitals, Leuven, Belgium; Mitchell R. Smith, Fox Chase Cancer Center, Philadelphia; Joseph Boni, Pfizer, Collegeville, PA; Peter Johnson, University of Southampton, Southhampton; Ama Rohatiner, St. Bartholomew's Hospital, London, United Kingdom; Jonathan L. Kaufman, Emory University, Atlanta, GA; Anjali Advani, Taussig Cancer Institute, The Cleveland Clinic, Cleveland, OH; James Foran, University of Alabama at Birmingham, Birmingham, AL; Georg Hess, Johannes Gutenberg University, Mainz, Germany; Bertrand Coiffier, Hospices Civils de Lyon and University Lyon, Lyon, France; Myron Czuczman, Roswell Park Cancer Institute, Buffalo, NY; Eva Giné, Hospital Clínic, Barcelona, Spain; Simon Durrant, Royal Brisbane Hospital, Brisbane, Australia; Michelle Kneissl and Erik Vandendries, Pfizer, Cambridge, MA; Kenneth T. Luu and Steven Y. Hua, Pfizer, La Jolla, CA; and Nam H. Dang, University of Florida, Gainesville, FL.</nlm:aff></affiliation></author><author><name sortKey="Boni, Joseph" sort="Boni, Joseph" uniqKey="Boni J" first="Joseph" last="Boni">Joseph Boni</name><affiliation><nlm:aff id="aff1">Luis Fayad, MD Anderson Cancer Center, Houston, TX; Fritz Offner, Ghent University Hospital, Ghent; Gregor Verhoef, University Hospitals, Leuven, Belgium; Mitchell R. Smith, Fox Chase Cancer Center, Philadelphia; Joseph Boni, Pfizer, Collegeville, PA; Peter Johnson, University of Southampton, Southhampton; Ama Rohatiner, St. Bartholomew's Hospital, London, United Kingdom; Jonathan L. Kaufman, Emory University, Atlanta, GA; Anjali Advani, Taussig Cancer Institute, The Cleveland Clinic, Cleveland, OH; James Foran, University of Alabama at Birmingham, Birmingham, AL; Georg Hess, Johannes Gutenberg University, Mainz, Germany; Bertrand Coiffier, Hospices Civils de Lyon and University Lyon, Lyon, France; Myron Czuczman, Roswell Park Cancer Institute, Buffalo, NY; Eva Giné, Hospital Clínic, Barcelona, Spain; Simon Durrant, Royal Brisbane Hospital, Brisbane, Australia; Michelle Kneissl and Erik Vandendries, Pfizer, Cambridge, MA; Kenneth T. Luu and Steven Y. Hua, Pfizer, La Jolla, CA; and Nam H. Dang, University of Florida, Gainesville, FL.</nlm:aff></affiliation></author><author><name sortKey="Vandendries, Erik" sort="Vandendries, Erik" uniqKey="Vandendries E" first="Erik" last="Vandendries">Erik Vandendries</name><affiliation><nlm:aff id="aff1">Luis Fayad, MD Anderson Cancer Center, Houston, TX; Fritz Offner, Ghent University Hospital, Ghent; Gregor Verhoef, University Hospitals, Leuven, Belgium; Mitchell R. Smith, Fox Chase Cancer Center, Philadelphia; Joseph Boni, Pfizer, Collegeville, PA; Peter Johnson, University of Southampton, Southhampton; Ama Rohatiner, St. Bartholomew's Hospital, London, United Kingdom; Jonathan L. Kaufman, Emory University, Atlanta, GA; Anjali Advani, Taussig Cancer Institute, The Cleveland Clinic, Cleveland, OH; James Foran, University of Alabama at Birmingham, Birmingham, AL; Georg Hess, Johannes Gutenberg University, Mainz, Germany; Bertrand Coiffier, Hospices Civils de Lyon and University Lyon, Lyon, France; Myron Czuczman, Roswell Park Cancer Institute, Buffalo, NY; Eva Giné, Hospital Clínic, Barcelona, Spain; Simon Durrant, Royal Brisbane Hospital, Brisbane, Australia; Michelle Kneissl and Erik Vandendries, Pfizer, Cambridge, MA; Kenneth T. Luu and Steven Y. Hua, Pfizer, La Jolla, CA; and Nam H. Dang, University of Florida, Gainesville, FL.</nlm:aff></affiliation></author><author><name sortKey="Dang, Nam H" sort="Dang, Nam H" uniqKey="Dang N" first="Nam H." last="Dang">Nam H. Dang</name><affiliation><nlm:aff id="aff1">Luis Fayad, MD Anderson Cancer Center, Houston, TX; Fritz Offner, Ghent University Hospital, Ghent; Gregor Verhoef, University Hospitals, Leuven, Belgium; Mitchell R. Smith, Fox Chase Cancer Center, Philadelphia; Joseph Boni, Pfizer, Collegeville, PA; Peter Johnson, University of Southampton, Southhampton; Ama Rohatiner, St. Bartholomew's Hospital, London, United Kingdom; Jonathan L. Kaufman, Emory University, Atlanta, GA; Anjali Advani, Taussig Cancer Institute, The Cleveland Clinic, Cleveland, OH; James Foran, University of Alabama at Birmingham, Birmingham, AL; Georg Hess, Johannes Gutenberg University, Mainz, Germany; Bertrand Coiffier, Hospices Civils de Lyon and University Lyon, Lyon, France; Myron Czuczman, Roswell Park Cancer Institute, Buffalo, NY; Eva Giné, Hospital Clínic, Barcelona, Spain; Simon Durrant, Royal Brisbane Hospital, Brisbane, Australia; Michelle Kneissl and Erik Vandendries, Pfizer, Cambridge, MA; Kenneth T. Luu and Steven Y. Hua, Pfizer, La Jolla, CA; and Nam H. Dang, University of Florida, Gainesville, FL.</nlm:aff></affiliation></author></analytic><series><title level="j">Journal of Clinical Oncology</title><idno type="ISSN">0732-183X</idno><idno type="eISSN">1527-7755</idno><imprint><date when="2013">2013</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><sec><title>Purpose</title><p>Inotuzumab ozogamicin (INO) is an antibody-targeted chemotherapy agent composed of a humanized anti-CD22 antibody conjugated to calicheamicin, a potent cytotoxic agent. We performed a phase I/II study to determine the maximum-tolerated dose (MTD), safety, efficacy, and pharmacokinetics of INO plus rituximab (R-INO) for treatment of relapsed/refractory CD20<italic><sup>+</sup></italic>/CD22<italic><sup>+</sup></italic> B-cell non-Hodgkin lymphoma (NHL).</p></sec><sec><title>Patients and Methods</title><p>A dose-escalation phase to determine the MTD of R-INO was followed by an expanded cohort to further evaluate the efficacy and safety at the MTD. Patients with relapsed follicular lymphoma (FL), relapsed diffuse large B-cell lymphoma (DLBCL), or refractory aggressive NHL received R-INO every 4 weeks for up to eight cycles.</p></sec><sec><title>Results</title><p>In all, 118 patients received one or more cycles of R-INO (median, four cycles). Most common grade 3 to 4 adverse events were thrombocytopenia (31%) and neutropenia (22%). Common low-grade toxicities included hyperbilirubinemia (25%) and increased AST (36%). The MTD of INO in combination with rituximab (375 mg/m<sup>2</sup>) was confirmed to be the same as that for single-agent INO (1.8 mg/m<italic><sup>2</sup></italic>). Treatment at the MTD yielded objective response rates of 87%, 74%, and 20% for relapsed FL (n = 39), relapsed DLBCL (n = 42), and refractory aggressive NHL (n = 30), respectively. The 2-year progression-free survival (PFS) rate was 68% (median, not reached) for FL and 42% (median, 17.1 months) for relapsed DLBCL.</p></sec><sec><title>Conclusion</title><p>R-INO demonstrated high response rates and long PFS in patients with relapsed FL or DLBCL. This and the manageable toxicity profile suggest that R-INO may be a promising option for CD20<italic><sup>+</sup></italic>/CD22<italic><sup>+</sup></italic> B-cell NHL.</p></sec></div></front></TEI><pmc article-type="research-article"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<front><journal-meta><journal-id journal-id-type="nlm-ta">J Clin Oncol</journal-id><journal-id journal-id-type="iso-abbrev">J. Clin. Oncol</journal-id><journal-id journal-id-type="hwp">jco</journal-id><journal-id journal-id-type="pmc">jco</journal-id><journal-id journal-id-type="publisher-id">JCO</journal-id><journal-title-group><journal-title>Journal of Clinical Oncology</journal-title></journal-title-group><issn pub-type="ppub">0732-183X</issn><issn pub-type="epub">1527-7755</issn><publisher><publisher-name>American Society of Clinical Oncology</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">23295790</article-id><article-id pub-id-type="pmc">4878046</article-id><article-id pub-id-type="publisher-id">27211</article-id><article-id pub-id-type="doi">10.1200/JCO.2012.42.7211</article-id><article-categories><subj-group subj-group-type="hwp-journal-coll"><subject>Hema14</subject></subj-group><subj-group subj-group-type="heading"><subject>ORIGINAL REPORTS</subject><subj-group><subject>Hematologic Malignancies</subject></subj-group></subj-group></article-categories><title-group><article-title>Safety and Clinical Activity of a Combination Therapy Comprising Two Antibody-Based Targeting Agents for the Treatment of Non-Hodgkin Lymphoma: Results of a Phase I/II Study Evaluating the Immunoconjugate Inotuzumab Ozogamicin With Rituximab</article-title><alt-title alt-title-type="short">Inotuzumab Ozogamicin Plus Rituximab for B-Cell NHL</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Fayad</surname><given-names>Luis</given-names></name><xref ref-type="aff" rid="aff1"></xref><xref ref-type="corresp" rid="cor1"></xref></contrib><contrib contrib-type="author"><name><surname>Offner</surname><given-names>Fritz</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Smith</surname><given-names>Mitchell R.</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Verhoef</surname><given-names>Gregor</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Johnson</surname><given-names>Peter</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Kaufman</surname><given-names>Jonathan L.</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Rohatiner</surname><given-names>Ama</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Advani</surname><given-names>Anjali</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Foran</surname><given-names>James</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Hess</surname><given-names>Georg</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Coiffier</surname><given-names>Bertrand</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Czuczman</surname><given-names>Myron</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Giné</surname><given-names>Eva</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Durrant</surname><given-names>Simon</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Kneissl</surname><given-names>Michelle</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Luu</surname><given-names>Kenneth T.</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Hua</surname><given-names>Steven Y.</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Boni</surname><given-names>Joseph</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Vandendries</surname><given-names>Erik</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Dang</surname><given-names>Nam H.</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><aff id="aff1">Luis Fayad, MD Anderson Cancer Center, Houston, TX; Fritz Offner, Ghent University Hospital, Ghent; Gregor Verhoef, University Hospitals, Leuven, Belgium; Mitchell R. Smith, Fox Chase Cancer Center, Philadelphia; Joseph Boni, Pfizer, Collegeville, PA; Peter Johnson, University of Southampton, Southhampton; Ama Rohatiner, St. Bartholomew's Hospital, London, United Kingdom; Jonathan L. Kaufman, Emory University, Atlanta, GA; Anjali Advani, Taussig Cancer Institute, The Cleveland Clinic, Cleveland, OH; James Foran, University of Alabama at Birmingham, Birmingham, AL; Georg Hess, Johannes Gutenberg University, Mainz, Germany; Bertrand Coiffier, Hospices Civils de Lyon and University Lyon, Lyon, France; Myron Czuczman, Roswell Park Cancer Institute, Buffalo, NY; Eva Giné, Hospital Clínic, Barcelona, Spain; Simon Durrant, Royal Brisbane Hospital, Brisbane, Australia; Michelle Kneissl and Erik Vandendries, Pfizer, Cambridge, MA; Kenneth T. Luu and Steven Y. Hua, Pfizer, La Jolla, CA; and Nam H. Dang, University of Florida, Gainesville, FL.</aff></contrib-group><author-notes><corresp id="cor1">Corresponding author: Luis Fayad, MD, Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Box 429, Houston, TX 77030; e-mail: <email>lefayad@mdanderson.org</email>.</corresp></author-notes><pub-date pub-type="ppub"><day>10</day><month>2</month><year>2013</year></pub-date><pub-date pub-type="epub"><day>7</day><month>1</month><year>2013</year></pub-date><pub-date pub-type="pmc-release"><day>7</day><month>1</month><year>2013</year></pub-date><pmc-comment> PMC Release delay is 0 months and 0 days and was based on the
<volume>31</volume><issue>5</issue><fpage>573</fpage><lpage>583</lpage><permissions><copyright-statement>© 2013 by American Society of Clinical Oncology</copyright-statement><copyright-year>2013</copyright-year></permissions><self-uri xlink:title="pdf" xlink:type="simple" xlink:href="zlj00513000573.pdf"></self-uri><abstract><sec><title>Purpose</title><p>Inotuzumab ozogamicin (INO) is an antibody-targeted chemotherapy agent composed of a humanized anti-CD22 antibody conjugated to calicheamicin, a potent cytotoxic agent. We performed a phase I/II study to determine the maximum-tolerated dose (MTD), safety, efficacy, and pharmacokinetics of INO plus rituximab (R-INO) for treatment of relapsed/refractory CD20<italic><sup>+</sup></italic>/CD22<italic><sup>+</sup></italic> B-cell non-Hodgkin lymphoma (NHL).</p></sec><sec><title>Patients and Methods</title><p>A dose-escalation phase to determine the MTD of R-INO was followed by an expanded cohort to further evaluate the efficacy and safety at the MTD. Patients with relapsed follicular lymphoma (FL), relapsed diffuse large B-cell lymphoma (DLBCL), or refractory aggressive NHL received R-INO every 4 weeks for up to eight cycles.</p></sec><sec><title>Results</title><p>In all, 118 patients received one or more cycles of R-INO (median, four cycles). Most common grade 3 to 4 adverse events were thrombocytopenia (31%) and neutropenia (22%). Common low-grade toxicities included hyperbilirubinemia (25%) and increased AST (36%). The MTD of INO in combination with rituximab (375 mg/m<sup>2</sup>) was confirmed to be the same as that for single-agent INO (1.8 mg/m<italic><sup>2</sup></italic>). Treatment at the MTD yielded objective response rates of 87%, 74%, and 20% for relapsed FL (n = 39), relapsed DLBCL (n = 42), and refractory aggressive NHL (n = 30), respectively. The 2-year progression-free survival (PFS) rate was 68% (median, not reached) for FL and 42% (median, 17.1 months) for relapsed DLBCL.</p></sec><sec><title>Conclusion</title><p>R-INO demonstrated high response rates and long PFS in patients with relapsed FL or DLBCL. This and the manageable toxicity profile suggest that R-INO may be a promising option for CD20<italic><sup>+</sup></italic>/CD22<italic><sup>+</sup></italic> B-cell NHL.</p></sec></abstract></article-meta></front></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 0004520 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 0004520 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé=
|texte=
}}
| This area was generated with Dilib version V0.6.33. |  |